78.78
Haemonetics Corp stock is traded at $78.78, with a volume of 462.74K.
It is up +1.78% in the last 24 hours and up +8.11% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$77.40
Open:
$78.32
24h Volume:
462.74K
Relative Volume:
0.53
Market Cap:
$3.58B
Revenue:
$1.33B
Net Income/Loss:
$97.31M
P/E Ratio:
38.78
EPS:
2.0317
Net Cash Flow:
$260.44M
1W Performance:
+1.18%
1M Performance:
+8.11%
6M Performance:
+14.47%
1Y Performance:
+6.09%
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corp
|
78.78 | 3.58B | 1.33B | 97.31M | 260.44M | 2.0317 |
|
ABT
Abbott Laboratories
|
103.06 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
330.25 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
83.21 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
44.25 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
82.63 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Haemonetics Corp (HAE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Haemonetics Corp (HAE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HAE|Haemonetics Corp|Price:79.045|Chg%:+1.645 - TradingKey
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada
Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies - GlobeNewswire Inc.
Haemonetics Corp (HAE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Haemonetics (HAE) Q4 2026 Earnings ReportResults, Call & Slides - TipRanks
HAE|Haemonetics Corp|Price:77.420|Chg%:-0.610 - TradingKey
Haemonetics stock trades steadily as recent earnings highlight blood management growth - AD HOC NEWS
Haemonetics stock trades steadily as revenue and earnings grow - AD HOC NEWS
Haemonetics (HAE) Could Be 10% Undervalued On Its Margin Expansion Story - simplywall.st
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $90 - 富途牛牛
HAE Maintained by Mizuho -- Price Target Raised to $90 - GuruFocus
Is Haemonetics Corp (HAE) a Bargain After 3.2% Drop? GF Value Sa - GuruFocus
HAE5817431 Bond Profile — Key Metrics - TradingView
Haemonetics (HAE) Joins Russell Indexes As Investors Ask If The Stock Is Still Undervalued - simplywall.st
HAE stock steadies as Haemonetics focuses on blood and plasma - AD HOC NEWS
HAE stock holds steady as investors track Haemonetics' product mix - AD HOC NEWS
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $79 - 富途牛牛
Haemonetics sets Aug. 6 call for Q1 2027 results - Stock Titan
Haemonetics (HAE) Analyst Adjusts Price Target Despite Neutral R - GuruFocus
Haemonetics Corp updates investors on blood management business. Operational focus supports long-ter - Ad-hoc-news.de
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corporation's $210 Million Cash Flow: Is The Transition Working? - Smartkarma
Daily Brief Health Care: Bausch Health Companies, Biodexa Pharmaceuticals, Fortrea Holdings , Haemonetics Corp, Legend Biotech Corp and more - Smartkarma
Haemonetics Corp updates plasma strategy, shares tracked against U.S. medtech peers - Ad-hoc-news.de
Haemonetics’ Broad Russell Value Index Inclusion Might Change The Case For Investing In Haemonetics (HAE) - simplywall.st
HAE Reiterated by BTIG -- Price Target Maintained at $84 - GuruFocus
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100 - GuruFocus
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $85 - 富途牛牛
Quietly ambitious, Haemonetics NexSys PCS pushes plasma efficiency further - AD HOC NEWS
Why Haemonetics’ NexSys PCS quietly reshapes plasma collection on the clinic floor - AD HOC NEWS
Haemonetics Corp (HAE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Haemonetics Corp (HAE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Haemonetics Corp (HAE) Institutional Confidence - TradingKey
Haemonetics Corp (HAE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Haemonetics Corp (HAE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Loomis Sayles Small Cap Core Portfolio's Haemonetics Corp(HAE) Holding History - GuruFocus
HAE Reiterated by BTIG -- Price Target Maintained at $84.00 - GuruFocus
Haemonetics Corp (HAE) Shares Fall 3.2% -- What GF Score of 77 T - GuruFocus
HAE: Upcoming Virtual Meeting Scheduled for June 24 - GuruFocus
HAE Maintained by Mizuho -- Price Target Raised to $85.00 - GuruFocus
Mizuho raises Haemonetics stock price target to $85 on plasma demand - Investing.com UK
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices? - simplywall.st
HAEMONETICS CORP ($HAE) President and CEO 2026 Pay Revealed - Quiver Quantitative
[ARS] HAEMONETICS CORP SEC Filing - Stock Titan
Executive pay and equity plans in Haemonetics (NYSE: HAE) 2026 proxy filing - Stock Titan
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment - Yahoo Finance
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):